Anti-hyperglycaemic agents have a role in preventing the development of DKD however agents such as glucagon-like peptide-1 receptor (GLP-1R) agonists have been shown to prevent the onset of microalbuminuria independently of glycaemic effects (Rowlands et al., 2018). This evidence concerns the gene GLP1R and diabetic kidney disease.